DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Solanezumab is an investigational drug.
There have been 10 clinical trials for Solanezumab. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2009.
The most common disease conditions in clinical trials are Alzheimer Disease, Cognition Disorders, and Mild Cognitive Impairment. The leading clinical trial sponsors are Eli Lilly and Company, Avid Radiopharmaceuticals, and Alzheimer's Association.
Recent Clinical Trials for Solanezumab
|A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease||Eli Lilly and Company||Phase 3|
|A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)||Eli Lilly and Company||Phase 1|
|Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss||Alzheimer's Therapeutic Research Institute||Phase 3|